Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
MARLBOROUGH, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the year ended December 31, 2023 and provided a business update.
- The latter clearance was significant since there are no drugs specifically approved to treat early stages I and II of cSCC.
- As of February, the first two patients in our first cohort have completed treatment with PH-762 with no reported adverse events.
- In 2023 we implemented a cost rationalization program driven by our transition from discovery research to product development.
- At December 31, 2023 we had cash of $8.5 million as compared with $11.8 million at December 31, 2022.